Learn More
The olfactory bulb as the entry site for prion-like propagation in
neurodegenerative diseases
Learn More

Diabetes drug slows experimental Parkinson’s disease progression,
human trials to begin next year



Patrik Brundin Laboratory
Research in Patrik Brundin’s laboratory focuses on pathogenetic mechanisms and pharmacological treatment in cell and animal models of Parkinson’s disease. The group’s mission is to understand neurodegenerative diseases and develop new therapies that are of benefit
to patients and their caregivers.

Learn More

In the Press

31 Jan. 2022 | Could Covid-19 still be affecting us in decades to come?
David Cox | BBC

19 Oct. 2021 | Podcast episode 115: Repurposing medications to slow progression of PD
Parkinson’s Foundation

22 March 2019 Patrik Brundin: life on the river
Adrian Burton | The Lancet

9 Oct. 2018 Linked Clinical Trials initiative boosts number of Parkinson’s clinical studies
Jose Marques Lopes, Ph.D | Parkinson’s News Today

26 Oct. 2016 Pathology: The prion principle


Grand Challenges in Parkinson's Disease
Grand Challenges in Parkinson's Disease

Registration is now open for the 2022 Grand Challenges in Parkinson's Disease symposium! Join us for another great year as...